about
Palliative surgery for rare cases of anterior urethral metastasis in prostate cancer.Influence of surgical complications on kidney graft survival in recipients of simultaneous pancreas kidney transplantation.Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.[Epidemiology of urinary lithiasis in Spain: New scenarios.]A tertiary experience of ileal-ureter substitution: Contemporary indications and outcomes.European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.Graft Survival in Patients Who Received Second Allograft, Comparing Those With or Without Previous Failed Allograft Nephrectomy.The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressivenessProstate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other OmicsThe management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry.Assessment and clinical factors associated with pain in patients undergoing transrectal prostate biopsy.Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.TEMPORARY REMOVAL: New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.Impact of 3D vision on mental workload and laparoscopic performance in inexperienced subjects.Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance.Initial Experience in the Use of Novel Auto-expandable Metal Ureteral Stent in the Treatment of Ureter Stenosis in Kidney Transplanted Patients.Prognostic value of penile colour doppler ultrasonography for recovering erectile function after radical prostatectomy.[When should we perform a bone scintigraphy in patients with new diagnosis of asymptomatic prostate cancer in order to detect bone metastasis?].Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillancePlasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancerPartial thrombosis of the corpus cavernosum: should we dig deeper into coagulopathy disorders?CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancerSpliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancerExpression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancerClinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer
P50
Q38243798-A28856DC-27DE-420F-822A-59326FBD5D65Q38342058-DD775F43-DBF8-4014-BDD9-28A6733B5F85Q38735971-881D4E94-ED3D-4663-AE78-C0EC8D385123Q40326051-101EB8DA-C99B-4EDF-8D56-433A2AE9319EQ40337579-21F46EF7-0EFB-4361-B858-CA8B7EB25D75Q40420181-3C9FF1D7-EEB0-4D8A-8DD1-895F70921708Q40434374-571E0E1F-742D-4B40-8118-992C6D233347Q41558039-F4AD0596-D3EC-4380-A07C-DD7198690660Q42359959-38454DA2-92E4-4C73-A8FF-0651C577F37FQ47444078-5839CD3C-B59A-47D3-A510-8D22F599B5C5Q47739397-F0128344-FCF3-43DC-AD39-51C3A8F97C80Q47805050-D1F1BD3B-51FF-4ED1-9CAC-62E65C172A39Q48551566-D21E9E97-C4EA-4B28-896E-98B2B7AC90A6Q50202707-8E11E9AA-1E8F-4D9D-8479-CA4A854509D2Q50608969-FCF6BC70-0F7D-4E87-8ECE-FEFDFAEB6A3CQ51407391-5776AE2E-7A40-4DCD-8A2F-EF3A8068DF75Q52630604-6343EB4F-D2A7-4A00-A9BC-028725003BBAQ53048573-917458F4-CF1E-4FAF-AB38-BAA45F797BD7Q53582641-B2CB41F3-4975-4A8D-B7BC-41CCE289E234Q57107930-B3159656-DFB2-44ED-AF2D-A6687C56999EQ58760499-49E9268C-BBD3-4B2D-A7BD-B7778248B2DAQ89152740-0F420E8D-5609-4C13-BB4B-26DAC8277190Q92052777-E772735D-C78A-4E9F-94F2-B201F0DBBFCDQ92175081-888202A6-AEB7-457B-8A8A-9CA09E4B4F03Q92973777-9B57EB61-FE6B-4870-87DB-B246F2F53B5BQ93204655-30C4B524-ED92-44AF-84FA-4E37DB4C7B13
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Enrique Gómez Gómez
@ast
Enrique Gómez Gómez
@en
Enrique Gómez Gómez
@es
Enrique Gómez Gómez
@sl
type
label
Enrique Gómez Gómez
@ast
Enrique Gómez Gómez
@en
Enrique Gómez Gómez
@es
Enrique Gómez Gómez
@sl
altLabel
E ; Gómez EG; E.G.Gómez; E. Gómez Gómez Gómez
@en
prefLabel
Enrique Gómez Gómez
@ast
Enrique Gómez Gómez
@en
Enrique Gómez Gómez
@es
Enrique Gómez Gómez
@sl
P106
P21
P31
P496
0000-0002-8753-3306